IDEAS home Printed from https://ideas.repec.org/f/pni273.html
   My authors  Follow this author

Louis Wilhelmus Niessen

Personal Details

First Name:Louis
Middle Name:Wilhelmus
Last Name:Niessen
Suffix:
RePEc Short-ID:pni273
[This author has chosen not to make the email address public]
http://www.jhsph.edu/faculty/directory/profile/4958/Niessen/Louis_W.

Affiliation

(60%) Liverpool School of Tropical Medicine (Liverpool School of Tropical Medicine)

http://www.lstmliverpool.ac.uk/research/departments/international-public-health
Liverpool, UK

(20%) Department of Health Policy and Management
Bloomberg School of Public Health
Johns Hopkins University

Baltimore, Maryland (United States)
http://www.jhsph.edu/dept/HPM/
RePEc:edi:sphjhus (more details at EDIRC)

(20%) Department of Economics
University of Warwick

Coventry, United Kingdom
http://www.warwick.ac.uk/fac/soc/Economics/
RePEc:edi:dewaruk (more details at EDIRC)

Research output

as
Jump to: Articles

Articles

  1. Baltussen, Rob & Youngkong, Sitapon & Paolucci, Francesco & Niessen, Louis, 2010. "Multi-criteria decision analysis to prioritize health interventions: Capitalizing on first experiences," Health Policy, Elsevier, vol. 96(3), pages 262-264, August.
  2. Hugh Gravelle & Werner Brouwer & Louis Niessen & Maarten Postma & Frans Rutten, 2007. "Discounting in economic evaluations: stepping forward towards optimal decision rules," Health Economics, John Wiley & Sons, Ltd., vol. 16(3), pages 307-317, March.
  3. de Bont, Antoinette & Zandwijken, Gladys & Stolk, Elly & Niessen, Louis, 2007. "Prioritisation by physicians in the Netherlands--The growth hormone example in drug reimbursement decisions," Health Policy, Elsevier, vol. 80(3), pages 369-377, March.
  4. Niezen, Maartje & de Bont, Antoinette & Stolk, Elly & Eyck, Arthur & Niessen, Louis & Stoevelaar, Herman, 2007. "Conditional reimbursement within the Dutch drug policy," Health Policy, Elsevier, vol. 84(1), pages 39-50, November.
  5. Frans Rutten & Werner Brouwer & Louis Niessen, 2005. "Practice guidelines based on clinical and economic evidence," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 91-93, June.
  6. Raymond C. W. Hutubessy & Louis W. Niessen & Rob F. Dijkstra & Ton F. Casparie & Frans F. Rutten, 2005. "Stochastic league tables: an application to diabetes interventions in the Netherlands," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 445-455, May.
  7. Polak, B. C. P. & Crijns, H. & Casparie, A. F. & Niessen, L. W., 2003. "Cost-effectiveness of glycemic control and ophthalmological care in diabetic retinopathy," Health Policy, Elsevier, vol. 64(1), pages 89-97, April.
  8. van Os, Nicole & Niessen, Louis W. & Bilo, Henk J. G. & Casparie, Anton F. & van Hout, Ben A., 2000. "Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines," Health Policy, Elsevier, vol. 51(3), pages 135-147, April.
  9. Niessen, Louis W. & Grijseels, Els W. M. & Rutten, Frans F. H., 2000. "The evidence-based approach in health policy and health care delivery," Social Science & Medicine, Elsevier, vol. 51(6), pages 859-869, September.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Articles

  1. Baltussen, Rob & Youngkong, Sitapon & Paolucci, Francesco & Niessen, Louis, 2010. "Multi-criteria decision analysis to prioritize health interventions: Capitalizing on first experiences," Health Policy, Elsevier, vol. 96(3), pages 262-264, August.

    Cited by:

    1. Craig Mitton & Brayan V. Seixas & Stuart Peacock & Michael Burgess & Stirling Bryan, 2019. "Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation," Applied Health Economics and Health Policy, Springer, vol. 17(5), pages 573-576, October.
    2. Scheil-Adlung, Xenia., 2015. "Global evidence on inequities in rural health protection : new data on rural deficits in health coverage for 174 countries," ILO Working Papers 994876213402676, International Labour Organization.
    3. Stanislav Shmelev & Harrison Roger Brook, 2021. "Macro Sustainability across Countries: Key Sector Environmentally Extended Input-Output Analysis," Sustainability, MDPI, vol. 13(21), pages 1-46, October.
    4. Nicholas Generous & Kristen J Margevicius & Kirsten J Taylor-McCabe & Mac Brown & W Brent Daniel & Lauren Castro & Andrea Hengartner & Alina Deshpande, 2014. "Selecting Essential Information for Biosurveillance—A Multi-Criteria Decision Analysis," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-15, January.
    5. Mónica D. Oliveira & Inês Mataloto & Panos Kanavos, 2019. "Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 891-918, August.
    6. Øystein Ariansen Haaland & Frode Lindemark & Kjell Arne Johansson, 2019. "A flexible formula for incorporating distributive concerns into cost-effectiveness analyses: Priority weights," PLOS ONE, Public Library of Science, vol. 14(10), pages 1-12, October.
    7. Hipgrave, David B. & Alderman, Katarzyna Bolsewicz & Anderson, Ian & Soto, Eliana Jimenez, 2014. "Health sector priority setting at meso-level in lower and middle income countries: Lessons learned, available options and suggested steps," Social Science & Medicine, Elsevier, vol. 102(C), pages 190-200.
    8. Axel C. Mühlbacher & Anika Kaczynski, 2016. "Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA," Applied Health Economics and Health Policy, Springer, vol. 14(1), pages 29-40, February.
    9. Mireille M. Goetghebeur & Monika Wagner & Hanane Khoury & Randy J. Levitt & Lonny J. Erickson & Donna Rindress, 2012. "Bridging Health Technology Assessment (HTA) and Efficient Health Care Decision Making with Multicriteria Decision Analysis (MCDA)," Medical Decision Making, , vol. 32(2), pages 376-388, March.
    10. Stuart J. Peacock & Craig Mitton, 2012. "Priority Setting Methods in Health Services," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 53, Edward Elgar Publishing.
    11. Axel C. Mühlbacher & John F. P. Bridges & Susanne Bethge & Ch.-Markos Dintsios & Anja Schwalm & Andreas Gerber-Grote & Matthias Nübling, 2017. "Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(2), pages 155-165, March.
    12. V. Meusel & E. Mentzakis & P. Baji & G. Fiorentini & F. Paolucci, 2023. "Priority setting in the German healthcare system: results from a discrete choice experiment," International Journal of Health Economics and Management, Springer, vol. 23(3), pages 411-431, September.
    13. Panos Kanavos & Olivier Wouters & Aris Angelis & Panos Kanavos & Gilberto Montibeller, 2017. "Resource Allocation and Priority Setting in Health Care: A Multi-criteria Decision Analysis Problem of Value?," Global Policy, London School of Economics and Political Science, vol. 8, pages 76-83, March.

  2. Hugh Gravelle & Werner Brouwer & Louis Niessen & Maarten Postma & Frans Rutten, 2007. "Discounting in economic evaluations: stepping forward towards optimal decision rules," Health Economics, John Wiley & Sons, Ltd., vol. 16(3), pages 307-317, March.

    Cited by:

    1. Arthur E. Attema & Werner B.F. Brouwer, 2014. "Deriving Time Discounting Correction Factors For Tto Tariffs," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 410-425, April.
    2. E. Wetering & E. Stolk & N. Exel & W. Brouwer, 2013. "Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 107-115, February.
    3. Basu, Anirban, 2020. "A welfare-theoretic model consistent with the practice of cost-effectiveness analysis and its implications," Journal of Health Economics, Elsevier, vol. 70(C).
    4. Arthur E. Attema & Werner B. F. Brouwer & Karl Claxton, 2018. "Discounting in Economic Evaluations," PharmacoEconomics, Springer, vol. 36(7), pages 745-758, July.
    5. Erik Nord, 2011. "Discounting future health benefits: the poverty of consistency arguments," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 16-26, January.
    6. Michael Spackman, 2011. "Government discounting controversies: changing prices, opportunity costs and systematic risk," GRI Working Papers 67, Grantham Research Institute on Climate Change and the Environment.
    7. M. Parouty & H. Le & D. Krooshof & M. Postma, 2014. "Differential Time Preferences for Money and Quality of Life," PharmacoEconomics, Springer, vol. 32(4), pages 411-419, April.
    8. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.
    9. James K. Hammitt, 2012. "Discounting Health And Cost‐Effectiveness Analysis: A Response To Nord," Health Economics, John Wiley & Sons, Ltd., vol. 21(7), pages 878-882, July.
    10. van der Pol, Marjon & Cairns, John, 2008. "Comparison of two methods of eliciting time preference for future health states," Social Science & Medicine, Elsevier, vol. 67(5), pages 883-889, September.
    11. Mike Paulden & Karl Claxton, 2012. "Budget allocation and the revealed social rate of time preference for health," Health Economics, John Wiley & Sons, Ltd., vol. 21(5), pages 612-618, May.
    12. E. Wetering & N. Exel & J. Rose & R. Hoefman & W. Brouwer, 2016. "Are some QALYs more equal than others?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(2), pages 117-127, March.
    13. Mike Paulden & Anthony J Culyer, 2010. "Does cost-effectiveness analysis discriminate against patients with short life expectancy? Matters of logic and matters of context," Working Papers 055cherp, Centre for Health Economics, University of York.
    14. Attema, Arthur E. & Brouwer, Werner B.F., 2009. "The correction of TTO-scores for utility curvature using a risk-free utility elicitation method," Journal of Health Economics, Elsevier, vol. 28(1), pages 234-243, January.
    15. Claxton, Karl & Asaria, Miqdad & Chansa, Collins & Jamison, Julian & Lomas, James & Ochalek, Jessica & Paulden, Mike, 2019. "Accounting for timing when assessing health-related policies," LSE Research Online Documents on Economics 100408, London School of Economics and Political Science, LSE Library.
    16. David Brain & Laith Yakob & Adrian Barnett & Thomas Riley & Archie Clements & Kate Halton & Nicholas Graves, 2018. "Economic evaluation of interventions designed to reduce Clostridium difficile infection," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-15, January.
    17. Ana Bobinac & N. Job A. van Exel & Frans F. H. Rutten & Werner B. F. Brouwer, 2013. "Valuing Qaly Gains By Applying A Societal Perspective," Health Economics, John Wiley & Sons, Ltd., vol. 22(10), pages 1272-1281, October.
    18. Martin Hoyle & Rob Anderson, 2010. "Whose Costs and Benefits? Why Economic Evaluations Should Simulate Both Prevalent and All Future Incident Patient Cohorts," Medical Decision Making, , vol. 30(4), pages 426-437, July.
    19. Bob J. H. van Kempen & Bart S. Ferket & Albert Hofman & Sandra Spronk & Ewout Steyerberg & M. G. Myriam Hunink, 2012. "Do Different Methods of Modeling Statin Treatment Effectiveness Influence the Optimal Decision?," Medical Decision Making, , vol. 32(3), pages 507-516, May.
    20. Karl Claxton & Mike Paulden & Hugh Gravelle & Werner Brouwer & Anthony J. Culyer, 2011. "Discounting and decision making in the economic evaluation of health‐care technologies," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 2-15, January.
    21. John Hutton, 2012. "‘Health Economics’ and the evolution of economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 21(1), pages 13-18, January.
    22. Werner Brouwer & Pieter Baal & Job Exel & Matthijs Versteegh, 2019. "When is it too expensive? Cost-effectiveness thresholds and health care decision-making," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 175-180, March.
    23. Karl Claxton & Mark Sculpher & Tony Culyer, 2007. "Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions," Working Papers 031cherp, Centre for Health Economics, University of York.
    24. Ana Bobinac & Job Exel & Frans Rutten & Werner Brouwer, 2014. "The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk," PharmacoEconomics, Springer, vol. 32(1), pages 75-86, January.
    25. N. J. Welton & A. E. Ades & D. M. Caldwell & T. J. Peters, 2008. "Research prioritization based on expected value of partial perfect information: a case‐study on interventions to increase uptake of breast cancer screening," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 171(4), pages 807-841, October.
    26. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022. "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 651-667, September.
    27. Mike Paulden & Anthony J. Culyer, 2010. "Does Cost-Effectiveness Analysis Discriminate against Patients with Short Life Expectancy?," Working Paper series 41_10, Rimini Centre for Economic Analysis.
    28. Mareike Schad & Jürgen John, 2012. "Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 127-144, April.
    29. Ana Bobinac & Werner Brouwer & Job van Exel, 2011. "Discounting future health gains: an empirical enquiry into the influence of growing life expectancy," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 111-119, January.

  3. de Bont, Antoinette & Zandwijken, Gladys & Stolk, Elly & Niessen, Louis, 2007. "Prioritisation by physicians in the Netherlands--The growth hormone example in drug reimbursement decisions," Health Policy, Elsevier, vol. 80(3), pages 369-377, March.

    Cited by:

    1. Kapiriri, Lydia & Razavi, Donya, 2017. "How have systematic priority setting approaches influenced policy making? A synthesis of the current literature," Health Policy, Elsevier, vol. 121(9), pages 937-946.
    2. Tania Stafinski & Devidas Menon & Deborah Marshall & Timothy Caulfield, 2011. "Societal Values in the Allocation of Healthcare Resources," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 4(4), pages 207-225, December.
    3. Kapiriri, Lydia & Norheim, Ole F. & Martin, Douglas K., 2009. "Fairness and accountability for reasonableness. Do the views of priority setting decision makers differ across health systems and levels of decision making?," Social Science & Medicine, Elsevier, vol. 68(4), pages 766-773, February.

  4. Niezen, Maartje & de Bont, Antoinette & Stolk, Elly & Eyck, Arthur & Niessen, Louis & Stoevelaar, Herman, 2007. "Conditional reimbursement within the Dutch drug policy," Health Policy, Elsevier, vol. 84(1), pages 39-50, November.

    Cited by:

    1. Bognar, Katalin & Romley, John A. & Bae, Jay P. & Murray, James & Chou, Jacquelyn W. & Lakdawalla, Darius N., 2017. "The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions," Journal of Health Economics, Elsevier, vol. 51(C), pages 1-12.
    2. Boon, Wouter & Martins, Luis & Koopmanschap, Marc, 2015. "Governance of conditional reimbursement practices in the Netherlands," Health Policy, Elsevier, vol. 119(2), pages 180-185.
    3. Tania Stafinski & Devidas Menon & Deborah Marshall & Timothy Caulfield, 2011. "Societal Values in the Allocation of Healthcare Resources," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 4(4), pages 207-225, December.
    4. Wasem, Jürgen & Weegen, Lennart & Bauer, Cosima & Walendzik, Anke & Grande, Frederic & May, Uwe, 2015. "Regulatorische Handhabung der selektiven Erstattung von Arzneimitteln in den ausgewählten Ländern England, Niederlande, Frankreich und Schweden," IBES Diskussionsbeiträge 211, University of Duisburg-Essen, Institute of Business and Economic Studie (IBES).

  5. Raymond C. W. Hutubessy & Louis W. Niessen & Rob F. Dijkstra & Ton F. Casparie & Frans F. Rutten, 2005. "Stochastic league tables: an application to diabetes interventions in the Netherlands," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 445-455, May.

    Cited by:

    1. H. Koffijberg & G. A. de Wit & T. L. Feenstra, 2012. "Communicating Uncertainty in Economic Evaluations," Medical Decision Making, , vol. 32(3), pages 477-487, May.

  6. Polak, B. C. P. & Crijns, H. & Casparie, A. F. & Niessen, L. W., 2003. "Cost-effectiveness of glycemic control and ophthalmological care in diabetic retinopathy," Health Policy, Elsevier, vol. 64(1), pages 89-97, April.

    Cited by:

    1. Sally Brailsford & Walter Gutjahr & Marion Rauner & Wolfgang Zeppelzauer, 2007. "Combined Discrete-event Simulation and Ant Colony Optimisation Approach for Selecting Optimal Screening Policies for Diabetic Retinopathy," Computational Management Science, Springer, vol. 4(1), pages 59-83, January.
    2. Julia Ting & Donald Martin & Marion Haas, 2007. "A Markov model of Diabetic Retinopathy Progression for the Economic Evaluation of a novel DR prognostic device, CHERE Working Paper 2007/14," Working Papers 2007/14, CHERE, University of Technology, Sydney.

  7. van Os, Nicole & Niessen, Louis W. & Bilo, Henk J. G. & Casparie, Anton F. & van Hout, Ben A., 2000. "Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines," Health Policy, Elsevier, vol. 51(3), pages 135-147, April.

    Cited by:

    1. Alexander V van Schoonhoven & Judith J Gout-Zwart & Marijke J S de Vries & Antoinette D I van Asselt & Evgeni Dvortsin & Pepijn Vemer & Job F M van Boven & Maarten J Postma, 2019. "Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-22, September.
    2. Polak, B. C. P. & Crijns, H. & Casparie, A. F. & Niessen, L. W., 2003. "Cost-effectiveness of glycemic control and ophthalmological care in diabetic retinopathy," Health Policy, Elsevier, vol. 64(1), pages 89-97, April.
    3. Mark Knezevic, 2006. "Estimating the Long-Term Costs of Diabetic Kidney Disease: an Economic Approach," Economics Discussion / Working Papers 06-06, The University of Western Australia, Department of Economics.
    4. Charles Christian Adarkwah & Afschin Gandjour & Maren Akkerman & Silvia M Evers, 2011. "Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov Model," PLOS ONE, Public Library of Science, vol. 6(10), pages 1-10, October.
    5. Daniel M. Sugrue & Thomas Ward & Sukhvir Rai & Phil McEwan & Heleen G. M. Haalen, 2019. "Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design," PharmacoEconomics, Springer, vol. 37(12), pages 1451-1468, December.
    6. Cornelis Boersma & Jarir Atthobari & Ron Gansevoort & Lolkje Jong-Van den Berg & Paul Jong & Dick Zeeuw & Lieven Annemans & Maarten Postma, 2006. "Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy," PharmacoEconomics, Springer, vol. 24(6), pages 523-535, June.

  8. Niessen, Louis W. & Grijseels, Els W. M. & Rutten, Frans F. H., 2000. "The evidence-based approach in health policy and health care delivery," Social Science & Medicine, Elsevier, vol. 51(6), pages 859-869, September.

    Cited by:

    1. Thomas Gries & Dirk Langeleh, 2004. "Anreizkompatibilität als zentrales Element eines neu gestalteten Gesundheitsmarktes," Perspektiven der Wirtschaftspolitik, Verein für Socialpolitik, vol. 5(3), pages 293-311, August.
    2. Lindič, Jaka & Bavdaž, Mojca & Kovačič, Helena, 2012. "Higher growth through the Blue Ocean Strategy: Implications for economic policy," Research Policy, Elsevier, vol. 41(5), pages 928-938.
    3. Gordon, Elisa Jill, 2006. "The political contexts of evidence-based medicine: Policymaking for daily hemodialysis," Social Science & Medicine, Elsevier, vol. 62(11), pages 2707-2719, June.
    4. Sogoric, Selma & Dzakula, Aleksandar & Rukavina, Tea Vukusic & Grozic-Zivolic, Sonja & Lazaric-Zec, Danijela & Dzono-Boban, Ankica & Brborovic, Ognjen & Lang, Slobodan & Vuletic, Silvije, 2009. "Evaluation of Croatian model of polycentric health planning and decision making," Health Policy, Elsevier, vol. 89(3), pages 271-278, March.
    5. Velasco Garrido, Marcial & Gerhardus, Ansgar & Røttingen, John-Arne & Busse, Reinhard, 2010. "Developing Health Technology Assessment to address health care system needs," Health Policy, Elsevier, vol. 94(3), pages 196-202, March.
    6. Ferlie, Ewan & Crilly, Tessa & Jashapara, Ashok & Peckham, Anna, 2012. "Knowledge mobilisation in healthcare: A critical review of health sector and generic management literature," Social Science & Medicine, Elsevier, vol. 74(8), pages 1297-1304.
    7. Gagnon, France & Turgeon, Jean & Dallaire, Clemence, 2007. "Healthy public policy: A conceptual cognitive framework," Health Policy, Elsevier, vol. 81(1), pages 42-55, April.
    8. Frans Rutten & Werner Brouwer & Louis Niessen, 2005. "Practice guidelines based on clinical and economic evidence," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 91-93, June.
    9. Lambert, Helen, 2006. "Accounting for EBM: Notions of evidence in medicine," Social Science & Medicine, Elsevier, vol. 62(11), pages 2633-2645, June.
    10. Mossialos, Elias & Naci, Huseyin & Courtin, Emilie, 2013. "Expanding the role of community pharmacists: Policymaking in the absence of policy-relevant evidence?," Health Policy, Elsevier, vol. 111(2), pages 135-148.
    11. de Bont, Antoinette & Zandwijken, Gladys & Stolk, Elly & Niessen, Louis, 2007. "Prioritisation by physicians in the Netherlands--The growth hormone example in drug reimbursement decisions," Health Policy, Elsevier, vol. 80(3), pages 369-377, March.
    12. Amy Weimann & Maylene Shung-King & Nicole McCreedy & Lambed Tatah & Clarisse Mapa-Tassou & Trish Muzenda & Ishtar Govia & Vincent Were & Tolu Oni, 2021. "Intersectoral Action for Addressing NCDs through the Food Environment: An Analysis of NCD Framing in Global Policies and Its Relevance for the African Context," IJERPH, MDPI, vol. 18(21), pages 1-17, October.
    13. Lars K. Hallstrom & Glen T. Hvenegaard, 2021. "Fostering Evidence-Informed Decision-Making for Protected Areas through the Alberta Parks Social Science Working Group," Land, MDPI, vol. 10(2), pages 1-15, February.
    14. Blume, Stuart & Tump, Janneke, 2010. "Evidence and policymaking: The introduction of MMR vaccine in the Netherlands," Social Science & Medicine, Elsevier, vol. 71(6), pages 1049-1055, September.
    15. Xiu-xia, Li & Ya, Zheng & Yao-long, Chen & Ke-hu, Yang & Zong-jiu, Zhang, 2015. "The reporting characteristics and methodological quality of Cochrane reviews about health policy research," Health Policy, Elsevier, vol. 119(4), pages 503-510.
    16. Kapiriri, Lydia & Norheim, Ole F. & Martin, Douglas K., 2009. "Fairness and accountability for reasonableness. Do the views of priority setting decision makers differ across health systems and levels of decision making?," Social Science & Medicine, Elsevier, vol. 68(4), pages 766-773, February.
    17. Chris Sampson & Bernarda Zamora & Sam Watson & John Cairns & Kalipso Chalkidou & Patricia Cubi-Molla & Nancy Devlin & Borja García-Lorenzo & Dyfrig A. Hughes & Ashley A. Leech & Adrian Towse, 2022. "Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 651-667, September.
    18. Gross, Revital, 2004. "A consumer-based tool for evaluating the quality of health services in the Israeli health care system following reform," Health Policy, Elsevier, vol. 68(2), pages 143-158, May.
    19. Robinson, Suzanne & Williams, Iestyn & Dickinson, Helen & Freeman, Tim & Rumbold, Benedict, 2012. "Priority-setting and rationing in healthcare: Evidence from the English experience," Social Science & Medicine, Elsevier, vol. 75(12), pages 2386-2393.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Louis Wilhelmus Niessen should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.